View : 432 Download: 0

Oral nanomedicine for modulating immunity, intestinal barrier functions, and gut microbiome

Title
Oral nanomedicine for modulating immunity, intestinal barrier functions, and gut microbiome
Authors
Lee, YonghyunKamada, NobuhikoMoon, James J.
Ewha Authors
이용현
SCOPUS Author ID
이용현scopus
Issue Date
2021
Journal Title
ADVANCED DRUG DELIVERY REVIEWS
ISSN
0169-409XJCR Link

1872-8294JCR Link
Citation
ADVANCED DRUG DELIVERY REVIEWS vol. 179
Keywords
Oral immunotherapyNanomedicineMucosal ImmunityPeyer's patchesLamina propriaIntestinal barrierGut microbiota
Publisher
ELSEVIER
Indexed
SCIE; SCOPUS WOS scopus
Document Type
Review
Abstract
The gastrointestinal tract (GIT) affects not only local diseases in the GIT but also various systemic diseases. Factors that can affect the health and disease of both GIT and the human body include 1) the mucosal immune system composed of the gut-associated lymphoid tissues and the lamina propria, 2) the intestinal barrier composed of mucus and intestinal epithelium, and 3) the gut microbiota. Selective delivery of drugs, including antigens, immune-modulators, intestinal barrier enhancers, and gutmicrobiome manipulators, has shown promising results for oral vaccines, immune tolerance, treatment of inflammatory bowel diseases, and other systemic diseases, including cancer. However, physicochemical and biological barriers of the GIT present significant challenges for successful translation. With the advances of novel nanomaterials, oral nanomedicine has emerged as an attractive option to not only overcome these barriers but also to selectively deliver drugs to the target sites in GIT. In this review, we discuss the GIT factors and physicochemical and biological barriers in the GIT. Furthermore, we present the recent progress of oral nanomedicine for oral vaccines, immune tolerance, and anti inflammation therapies. We also discuss recent advances in oral nanomedicine designed to fortify the intestinal barrier functions and modulate the gut microbiota and microbial metabolites. Finally, we opine about the future directions of oral nano-immunotherapy. (c) 2021 Elsevier B.V. All rights reserved.
DOI
10.1016/j.addr.2021.114021
Appears in Collections:
약학대학 > 약학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

BROWSE